AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment

  • New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®.
  • Study highlights importance of improving treatment “persistence” over time for long-term respiratory diseases.
  • Analysis, published in leading medical journal, is largest European Real-World Evidence study ever conducted in asthma and COPD.

[1] Seretide® and Diskus® are registered trademarks owned by Glaxo Group Ltd.

Holzkirchen, August 31, 2016 – New data just …

/by

AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment

  • New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®.
  • Study highlights importance of improving treatment “persistence” over time for long-term respiratory diseases.
  • Analysis, published in leading medical journal, is largest European Real-World Evidence study ever conducted in asthma and COPD.

[1] Seretide® and Diskus® are registered trademarks owned by Glaxo Group Ltd.

Holzkirchen, August 31, 2016 – New data just …

/by